Featured Press Releases

OmniSYS rebrands as XiFin Pharmacy Solutions, launches Pharmacy Payor Rate Transparency Monitor, and earns the Pharmacy 500 Award

OmniSYS rebrands as XiFin Pharmacy Solutions, launches Pharmacy Payor Rate Transparency Monitor, and earns the Pharmacy 500 Award

LIB Therapeutics Announces Positive Lerodalcibep Results from Two Phase 3 LIBerate Studies

LIB Therapeutics Announces Positive Lerodalcibep Results from Two Phase 3 LIBerate Studies

  • 29 May 2024

LIB Therapeutics Inc. (LIB), a privately-held, late-stage biopharmaceutical company advancing...

Dipal Doshi has been elected to Azenta

Dipal Doshi has been elected to Azenta's Board of Directors

Hanmi Pharmaceutical and Beijing Hanmi advance clinical trials for BH3120, their co-developed next-generation cancer immunotherapy

Hanmi Pharmaceutical and Beijing Hanmi advance clinical trials for BH3120, their co-developed next-generation cancer immunotherapy

Novel Compound AC102 Makes Constant Ear Noise Disappear in Preclinical Model: Tinnitus Research

Novel Compound AC102 Makes Constant Ear Noise Disappear in Preclinical Model: Tinnitus Research

LIfT BioSciences will present preclinical data on its first-in-class Immunomodulatory Alpha Neutrophils at the 40th Society for Immunotherapy of Cancer

LIfT BioSciences will present preclinical data on its first-in-class Immunomodulatory Alpha Neutrophils at the 40th Society for Immunotherapy of Cancer

FDA Grants KORU Medical Systems 510(k) Clearance for RYSTIGGO® Delivery via FreedomEDGE® Infusion System

FDA Grants KORU Medical Systems 510(k) Clearance for RYSTIGGO® Delivery via FreedomEDGE® Infusion System

  • KORU Medical Systems, Inc.
  • 02 Feb 2026
Tonix Pharmaceuticals presented Phase 3 RESILIENT data on TONMYA™ (cyclobenzaprine HCl sublingual tablets) at the 2026 Non-Opioid Pain Therapeutics Summit

Tonix Pharmaceuticals presented Phase 3 RESILIENT data on TONMYA™ (cyclobenzaprine HCl sublingual tablets) at the 2026 Non-Opioid Pain Therapeutics Summit

  • Tonix Pharmaceuticals Holding Corp.
  • 30 Jan 2026
China approves Libevitug, first-in-class therapy for hepatitis D

China approves Libevitug, first-in-class therapy for hepatitis D

  • Huahui Health Ltd.
  • 28 Jan 2026
DARZALEX FASPRO® quadruplet approved in U.S. for transplant-ineligible multiple myeloma patients

DARZALEX FASPRO® quadruplet approved in U.S. for transplant-ineligible multiple myeloma patients

  • Johnson & Johnson
  • 27 Jan 2026
Correction — Privo Technologies

Correction — Privo Technologies

  • Privo Technologies
  • 26 Jan 2026
HanchorBio Partners with WuXi Biologics to Advance Next-Generation Fusion Protein Pipeline

HanchorBio Partners with WuXi Biologics to Advance Next-Generation Fusion Protein Pipeline

  • HanchorBio Inc.
  • 26 Jan 2026
Drug Discovery 2024
The Digital Pharma Advances Conference 2026

Most Popular
February   2026
M T W T F S S
            1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28  

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.